Cargando…

2736. Real-world Effectiveness of Posaconazole Prophylaxis in Preventing Invasive Fungal Infections in Recipients of Allogeneic Stem Cell Transplantation

BACKGROUND: Invasive fungal infections (IFIs) can cause high morbidity and mortality in immunocompromised patients. Posaconazole is a commonly used triazole antifungal agent for prophylaxis against IFIs in high-risk populations. However, the effectiveness of Posaconazole as antifungal prophylaxis in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Álvarez-Ortega, Carolina, Muñoz-Lombo, Jenny Patricia, Rebellon-Sanchez, David E, Llanos-Torres, Julio, Rosso, Fernando, Vélez, Juan Diego, Moncada, Pablo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677699/ http://dx.doi.org/10.1093/ofid/ofad500.2347

Ejemplares similares

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
por: Ye, Peipei, et al.
Publicado: (2022)

1505. Clinical characterization of TB/HIV naive coinfection patients enrolled in a TB program in Cali - Colombia.
por: Muñoz-Lombo, Jenny Patricia, et al.
Publicado: (2023)

661. Mortality Rates and Resistance Profiles of Salmonella spp. Infections: Implications for Clinical Practice and Public Health Interventions
por: Rosso, Fernando, et al.
Publicado: (2023)

1734. Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience in Colombia
por: Estacio, Mayra, et al.
Publicado: (2019)

440. Steroid Use and Elevated Rates of Coinfections and Mortality in Mild-COVID-19 Patients
por: Rebellon-Sanchez, David E, et al.
Publicado: (2023)

Prophylaxis for invasive fungal infection in pediatric patients with allogeneic hematopoietic stem cell transplantation
por: Perez, Paola, et al.
Publicado: (2022)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

Posaconazole in the management of refractory invasive fungal infections
por: Langner, Stefan, et al.
Publicado: (2008)

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Tallman, Gregory B, et al.
Publicado: (2017)

Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Furuno, Jon P., et al.
Publicado: (2018)

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation
por: Döring, Michaela, et al.
Publicado: (2012)

Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
por: Takpradit, Chayamon, et al.
Publicado: (2021)

2311. Predictive cut-off values for anti-N and anti-S antibodies for COVID-19 risk identification
por: Rebellón Sánchez, David E, et al.
Publicado: (2023)

2312. COVID-19 risk factors before and after the vaccines among hospital workers: Have they changed?
por: Rosso, Fernando, et al.
Publicado: (2023)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

Limitations of the Check Calculation for Tooth Deformation of Plastic Gears According to Gear Design Guideline VDI 2736
por: Herzog, Christoph, et al.
Publicado: (2023)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

Efficacy of Posaconazole Prophylaxis for Fungal Disease in Hematology Patients Treated With Chemotherapy and Transplantation: An Open-Label, Prospective, Observational Study
por: Li, Weiyang, et al.
Publicado: (2020)

Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study
por: Chen, Xiaochen, et al.
Publicado: (2021)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection
por: Allegra, Sarah, et al.
Publicado: (2017)

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
por: Kang, Seung Hun, et al.
Publicado: (2015)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Cost-Effectiveness of Targeted Prophylaxis among Allogenic Stem Cell Transplant Recipients
por: Shbaklo, Nour, et al.
Publicado: (2023)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold, Nathan P
Publicado: (2015)

Dosing Optimization of Posaconazole in Lung-Transplant Recipients Based on Population Pharmacokinetic Model
por: Dvořáčková, Eliška, et al.
Publicado: (2023)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole
por: Soysal, Ahmet
Publicado: (2015)

Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea
por: Yang, Eunmi, et al.
Publicado: (2021)

Clinicopathological Features and Survival of Patients with Gastric Cancer with a Family History: a Large Analysis of 2,736 Patients with Gastric Cancer
por: Jeong, Oh, et al.
Publicado: (2017)

2736. Insurance Disparity in United States Cancer Survivors’ Influenza Vaccination Rates: A Trend Study from NHIS 2005–2017
por: Zheng, Xin, et al.
Publicado: (2019)

Pulmonary Phaeohyphomycosis Caused by Phaeoacremonium in a Kidney Transplant Recipient: Successful Treatment with Posaconazole
por: Monaganti, Saivaralaxmi, et al.
Publicado: (2014)

Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients
por: Ju, Chunrong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fag09cmhbjv1v29qhnq2mse1kq